Bright Minds Biosciences Inc. (DRUG) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
DRUG EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
DRUG Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export DRUG earnings history in CSV or JSON format
Free sign-in required to download data
Bright Minds Biosciences Inc. (DRUG) Earnings Overview
As of May 8, 2026, Bright Minds Biosciences Inc. (DRUG) reported trailing twelve-month net income of -$11M, reflecting -96.9% year-over-year growth. The company earned $-1.55 per diluted share over the past four quarters.
Looking at the long-term picture, DRUG's historical earnings data spans multiple years. The company achieved its highest annual net income of -$236,151 in fiscal 2019.
Bright Minds Biosciences Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CMPS (-$288M net income), ATAI (-$154M net income, -48464.0% margin), MNMD (-$238M net income), DRUG has comparable earnings metrics. Compare DRUG vs CMPS →
DRUG Earnings vs Peers
Earnings metrics vs comparable public companies
DRUG Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | -336.5% | -$14M | $-1.28 | - | - |
| 2024 | -$3M | +62.0% | -$3M | $-0.65 | - | - |
| 2023 | -$7M | +50.7% | -$7M | $-1.98 | - | - |
| 2022 | -$15M | -73.0% | -$15M | $-6.15 | - | - |
| 2021 | -$9M | -1700.8% | -$9M | $-4.74 | - | - |
| 2020 | $-480,377 | -103.4% | $-474,926 | $-0.38 | - | - |
| 2019 | $-236,151 | - | $-236,151 | $-0.06 | - | - |
See DRUG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DRUG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DRUG vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDRUG — Frequently Asked Questions
Quick answers to the most common questions about buying DRUG stock.
Is DRUG growing earnings?
DRUG EPS fell to $-1.55, with earnings declining -96.9%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-11M.
What are DRUG's profit margins?
Bright Minds Biosciences Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are DRUG's earnings?
DRUG earnings data spans 2019-2025. The declining earnings trend is -96.9% YoY. Historical data enables comparison across business cycles.